McKay Urology has an active research program in both clinical and basic science research. Dr. Teigland and his research group are currently running several clinical trials in the areas of prostate and kidney cancer treatment. Dr. Kennelly heads a research team that conducts clinical trials for the management of neurogenic/overactive bladder and urinary incontinence. Dr. Laura Neese Glasscock heads the basic science research. McKay Urology is also committed to the advancement of urologic surgical procedures and regularly tracks outcomes for the treatment of renal and prostate cancers.
Faculty Research Interests
Chris Teigland, MD, FACS
Chair and Director
Research Interests: Urologic Oncology: Prostate Cancer, Kidney Cancer
Dr. Teigland received his Doctor of Medicine from Duke University and spent two years in general surgery residency at the University of Utah in Salt Lake City. He then continued to the University of Texas - Southwestern in Dallas for four years of residency in urology. Dr. Teigland’s clinical practice and research focus is urologic oncology, particularly in the areas of kidney and prostate cancer. Dr. Teigland is involved in clinical trials for the treatment of advanced prostate cancer, benign prostatic hyperplasia, and advanced renal cell carcinoma (see below). In addition, both he and Dr. Laura Neese Glasscock are investigating angiogenesis and metastasis of prostate cancer via thrombomodulin expression.
Selected Clinical Trials
Antigenics C-100-12, “A Multi-Center, Randomized Phase III Study of Adjuvant Oncophage® Versus Observation in Patients with High Risk of Recurrence After Surgical Treatment for Renal Cell Carcinoma” (Antigenics, Inc.).
D9902B, “A Double-Blind, Randomized, Placebo-Controlled Phase III Trial of Immunotherapy with Autologous Antige Presenting Cells Loaded with PA2024 (Provenge®, APC8015) In Men With Metastatic, Androgen Independent Prostatic Adenocarcinoma” (Dendreon Corporation).
REDUCE ARI40006, “A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study of the Efficacy and Safety of Dutasteride 0.5mg Administered Orally Once Daily for Four Years to Reduce the Risk of Biopsy-Detectable Prostate Cancer” (GlaxoSmithKline).
All clinical trials conducted in Dr. Teigland’s practice are funded by the sponsor company of each trial.
Greene FL, Kercher KW, Nelson H, Teigland CM, Boller AM. Minimal access cancer management. CA Cancer J Clin 2007; 57: 130-146. [PMID: 17507440]
Barkin J, Beccia D, Belkoff L, Bock D, Chin J, Columbo G, Cookson M, Beeths J, Dineen M, Feldman S, Fisher H, Freeman J, Gittleman M, Immergut M, Kassabian V, Mackintosh R, Oswalt C, Pittman W, Saltzstein D, Schlegel P, Seidman E, Shore N, Seiber P, Teigland C, Trachtenberg J, Vestal J. Efficacy and safety of histrelin subdermal implant in patients with advanced prostate cancer. J Urol 2006; 175: 1353-1358. [PMID: 16515997]
Kang DE, White RL Jr, Zuger JH, Sasser HC, Teigland CM. Clinical use of fluorodeoxyglucose F 18 positron emission tomography for detection of renal cell carcinoma. J Urol 2004; 171: 1806-1809. [PMID: 15076281]
Current, Recent and Pending Research Grant Support
Grant Title: The Role of Thrombomodulin in Prostate Cancer-Associated Angiogenesis
Funding Agency: IDeA Networks of Biomedical Research Excellence (SC-INBRE) Molecular Biomedical Research Initiative at Winthrop University
Role: Project Mentor
Research Interests: Neurourology: Stress Urinary Incontinence, Neurogenic Bladder, Interstitial Cystitis, Pelvic Pain/Reconstruction
Dr. Kennelly received his Doctor of Medicine from the University of Cincinnati and spent his surgical internship and urology residency years at the University of Michigan Medical Center in Ann Arbor. He then completed a neurourology fellowship at the University of Texas – Houston. Dr. Kennelly’s research and clinical practice focuses on female urology, incontinence, and bladder problems caused by neurologic injury or disease. Dr. Kennelly is involved in clinical trials for the treatment of neurogenic bladder with BOTOX, male urinary sling systems and improvement of catheters (see below). He works closely with his staff at McKay Urology as well Carolinas Rehabilitation.
Selected Current Clinical Trials
Allergan Ltd, 191622-515, “A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel Group Study of the Safety and Efficacy of Repeat Treatment with Two Dose Levels of BOTOX (Botulinum Toxin Type A) Purified Neurotoxin Complex Followed by a Treatment with BOTOX in Patients With Urinary Incontinence Due to Neurogenic Detrusor Overactivity.”
American Medical Systems, AMS051, “A Pre-Marketed Study of the AMS Transobturator Male Sling System for the Treatment of Male Stress Urinary Incontinence.”
Coloplast A/S, “A Prospective, Randomized, Parallel Group, Multicenter Study to Compare the Occurrence of Urinary Tract Infections in Patients with Spinal Cord Injury Using Either Coated or Uncoated Intermittent Catheters.”
All clinical trials under Dr. Kennelly’s supervision are funded by the sponsor company of each trial.
Alexander MS, Marino R, Kennelly M, Krassioukow A, Stiens S. Autonomic standards and SCI: Preliminary considerations. Top Spinal Cord Inj Rehabil 2006; 11: 101-109. [Abstract]
Giuliano F, Rubio-Aurioles E, Kennelly M, Montorsi F, Kim ED, Finkbeiner AE, Pommerville PJ, Colopy MW, Wilkins HJ, Wachs BH; Vardenafil Study Group. Efficacy and safety of vardenafil in men with erectile dysfunction caused by spinal cord injury. Neurology 2006; 66: 210-216. [PMID: 16434656]
Chen TY, Ponsot Y, Carmel M, Bouffard N, Kennelly MJ, Tu LM. Multi-centre study of intraurethral valve-pump catheter in women with a hypocontractile or acontractile bladder.
Eur Urol 2005; 48: 628-633. [PMID: 15964124]
McKay Urology Basic Science Research
Chris Teigland, MD, FACS
Director, McKay Urology
Prostate Cancer Progression
The research efforts of the Urology Research Laboratory focus on the relationship between specific proteins involved prostate cancer metastasis and angiogenesis. This group is interested in how transmembrane proteins and their ligands facilitate prostate tumor cell adhesion and invasion. They are also interested in how these proteins regulate endothelial cell adhesion and microvessel formation. In addition, they are collecting and maintaining a long-term bank and database of prostate cancer tissue and serum in order to analyze the epidemiology of this disease.
The Urology Research basic science research projects began in 1996 when Chris Teigland, MD, collaborated with Douglas Price, PhD, on a project investigating the use of RT-PCR to characterize metastasizing prostate tumor cells. Laura Neese Glasscock, PhD, joined the research laboratory in 1997 and remains the Assistant Director of the research program. Since Dr. Glasscock’s arrival, the research interests of the laboratory have focused on the expression and activity of transmembrane receptors on prostate tumor cells and their ligands.
One of the proteins of interest in this laboratory is the transmembrane receptor, thrombomodulin (TM). Although this receptor is normally only expressed by endothelial cells where it regulates coagulation, this group has demonstrated that TM is also present on prostate tumor cells in vivo and on the prostate cell lines PC-3, DU-145, and LNCaP. They have also shown that patients with CaP have elevated levels of TM in serum and tissue compared to patients with benign prostatic hyperplasia and control. They have also demonstrated that TM on prostate tumor cells can bind to the serine protease, thrombin, and activate the zymogen protein C into activated protein C (APC). Furthermore, they have shown that TM regulates the ability of prostate tumor cells to adhere to each other and invade in an in vitro model, processes that are necessary for tumor metastasis. They have also shown that TM regulates these same activities on endothelial cells which suggests a role for TM in regulating angiogenesis.